Health Care & Life Sciences » Biotechnology | Stemline Therapeutics Inc.

Stemline Therapeutics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
654.20
1,041.40
898.20
500
Cost of Goods Sold (COGS) incl. D&A
76.70
153.30
-
-
-
-
Gross Income
76.70
153.30
-
-
-
-
SG&A Expense
23,973.80
29,171.80
38,133.70
39,846.60
69,442.00
86,730
EBIT
24,050.50
29,325.20
37,633.40
38,885.50
68,558.40
86,286.70
Unusual Expense
30.40
-
-
-
-
-
Non Operating Income/Expense
321.30
338.90
1.60
11.40
6.30
7.50
Interest Expense
516.90
-
-
-
-
0.80
Pretax Income
24,196.50
28,830.00
37,243.90
38,328.30
67,828.40
85,024.40
Income Tax
-
-
-
25.30
-
-
Consolidated Net Income
24,196.50
28,830.00
37,243.90
38,303.00
67,828.40
85,024.40
Net Income
24,196.50
28,830.00
37,243.90
38,303.00
67,828.40
85,024.40
Net Income After Extraordinaries
24,196.50
28,830.00
37,243.90
38,303.00
67,828.40
85,024.40
Net Income Available to Common
24,196.50
28,830.00
37,243.90
38,303.00
67,828.40
85,024.40
EPS (Basic)
2.35
2.23
2.15
2.15
2.94
2.99
Basic Shares Outstanding
10,317.40
12,936.70
17,289.00
17,804.70
23,056.90
28,388.90
EPS (Diluted)
2.35
2.23
2.15
2.15
2.94
2.99
Diluted Shares Outstanding
10,317.40
12,936.70
17,289.00
17,804.70
23,056.90
28,388.90
EBITDA
23,973.80
29,171.90
37,479.60
38,805.20
68,543.80
86,230
Non-Operating Interest Income
19.10
156.30
387.90
545.70
736.30
1,270.60

About Stemline Therapeutics

View Profile
Address
750 Lexington Avenue
New York New York 10022
United States
Employees -
Website http://www.stemline.com
Updated 07/08/2019
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.